Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 106 to 120 of 264 results for carcinoma

  1. Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy (TA788)

    Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.

  2. Laparoscopic cryotherapy for renal cancer (HTG271)

    Evidence-based recommendations on laparoscopic cryotherapy for renal cancer. This involves inserting a surgical instrument (cryoprobe) to apply freezing temperatures to the tumour and destroy the cancer cells.

  3. Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [ID6605]

    Awaiting development Reference number: GID-TA11751 Expected publication date: TBC

  4. Percutaneous cryotherapy for renal cancer (HTG269)

    Evidence-based recommendations on percutaneous cryotherapy for renal tumours. This involves inserting instruments that apply cold temperatures into the tumour to destroy the cancer cells.

  5. Guidance and quality standards in consultation

    See a complete list of all our guidance and quality standards currently open for consultation

  6. Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)

    Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.

  7. Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]

    Awaiting development Reference number: GID-TA11670 Expected publication date: TBC

  8. Surgery to the breast:- What is the optimum tumour-free margin width after breast-conserving surgery for women with ductal carcinoma in situ (DCIS) and invasive breast cancer?

    tumour-free margin width after breast-conserving surgery for women with ductal carcinoma in situ (DCIS) and invasive breast cancer? Any...

  9. Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)

    Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of invasive urothelial cancer at high risk of recurrence.

  10. Belzutifan with pembrolizumab for adjuvant treatment of clear cell renal cell carcinoma after nephrectomy [ID6645]

    In development Reference number: GID-TA11813 Expected publication date: TBC

  11. Sunlight exposure: risks and benefits (NG34)

    This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.

  12. Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]

    In development Reference number: GID-TA11774 Expected publication date:  30 September 2026

  13. Flexible endoscopic treatment of a pharyngeal pouch (HTG367)

    Evidence-based recommendations on flexible endoscopic treatment of a pharyngeal pouch. This involves improving swallowing by widening the neck of the pouch so that food does not collect in it.

  14. Catheterless oesophageal pH monitoring (HTG121)

    Evidence-based recommendations on catheterless oesophageal pH monitoring. This involves placing a small wireless capsule in the gullet to check the level of acid.

  15. Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessment (HTG746)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway.